Revenue from Contracts with Customers

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

3.   Revenue from Contracts with Customers. We recognize revenue when a customer obtains control of promised goods. The amount of revenue recognized reflects the consideration we expect to receive in exchange for these goods. Our revenue recognition policies have not changed from those disclosed in Note 1 to our consolidated financial statements in Item 8 of the 2024 Annual Report on Form 10-K.

Disaggregation of Revenue

Our revenue is disaggregated based on reporting segment, product category and geographic region. We design, develop, manufacture and market medical products for interventional, diagnostic and therapeutic procedures. For financial reporting purposes, we report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer (“OEM”). Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures.

The following tables present revenue from contracts with customers by reporting segment, product category and geographic region for the three and nine-month periods ended September 30, 2025 and 2024 (in thousands):

	Three Months Ended						Three Months Ended
	September 30, 2025						September 30, 2024*
	United States		International		Total		United States		International		Total
Cardiovascular
Peripheral Intervention	$	84,550	$	60,231	$	144,781	$	79,521	$	53,562	$	133,083
Cardiac Intervention		49,611		67,071		116,682		37,240		53,000		90,240
Custom Procedural Solutions		33,508		20,628		54,136		30,730		19,725		50,455
OEM		46,112		4,714		50,826		42,841		6,236		49,077
Total		213,781		152,644		366,425		190,332		132,523		322,855
Endoscopy
Endoscopy Devices		16,816		916		17,732		16,160		830		16,990
Total	$	230,597	$	153,560	$	384,157	$	206,492	$	133,353	$	339,845

	Nine Months Ended						Nine Months Ended
	September 30, 2025						September 30, 2024*
	United States		International		Total		United States		International		Total
Cardiovascular
Peripheral Intervention	$	248,694	$	176,213	$	424,907	$	231,952	$	165,583	$	397,535
Cardiac Intervention		137,110		194,564		331,674		109,407		164,316		273,723
Custom Procedural Solutions		95,446		60,266		155,712		90,438		58,672		149,110
OEM		140,072		16,798		156,870		120,232		23,444		143,676
Total		621,322		447,841		1,069,163		552,029		412,015		964,044
Endoscopy
Endoscopy Devices		49,921		2,886		52,807		35,221		2,091		37,312
Total	$	671,243	$	450,727	$	1,121,970	$	587,250	$	414,106	$	1,001,356

*Commencing January 1, 2025, we reorganized our sales teams and product categories to include revenues from the sale of our spine devices under our OEM product category. Revenue figures for 2024 have been recast to reflect this realignment of our portfolio of spine products, representing approximately $5.7 million and $16.7 million in revenue for the three and nine-month periods ended September 30, 2024, within the OEM product category to provide comparability between the reported periods.